Rubicon Limited is a New Zealand-based company listed on the main board of the New Zealand Stock Exchange (NZX:RBC). Approximately 70% of Rubicon’s issued shares are held by US beneficial holders. Rubicon Directors David Knott of Knott Partners and Ranjan Tandon of Libra Funds LP are each substantial shareholders in Rubicon. Knott Partners & Associates and Libra Funds LP owns 28.3% and 17.6% respectively of Rubicon’s issued share capital. In addition a further 3% is held by Independent Directors and management.

Rubicon was formed out of the separation of New Zealand’s largest industrial company at that time, Fletcher Challenge Limited. As part of this separation, Rubicon began life with a portfolio of energy and forestry assets. All the energy assets were subsequently disposed for NZ$118 million, with NZ$92 million being returned to shareholders by way of on-market share buyback programmes, and the residual being retained for subsequent investment into its forestry portfolio.

More recently Rubicon has exited from its investment in wood products manufacturing and global distribution business (Tenon) and the funds were used to enable Rubicon to increase its ownership interest in ArborGen Inc (“ArborGen”) to 100%, in June 2017. ArborGen is now Rubicon’s sole focus moving forward.

Please click on the ArborGen heading above to learn more about this business.



Forward Looking Statements

There are statements in this website that are “forward looking statements.” As these forward-looking statements are predictive in nature, they are subject to a number of risks and uncertainties relating to Rubicon, and our ArborGen investment, some of which are beyond our control. As a result of the foregoing, actual results and conditions may differ materially from those expressed or implied by such statements.  ArborGen’s risks and uncertainties include the economic conditions in the countries in which it operates and the wood product markets (commercial and residential, construction, pulp and paper etc), intellectual property protection, regulatory approvals, public and customer acceptance of genetically engineered products, customer adoption of advanced seedling products, the success of ArborGen’s research and development activities, weather conditions and biological matters. As a result of the foregoing, actual results and conclusions may differ materially from those expressed or implied by such statements.